CoChat
Sign Up
Cited by 38Diabetes Treatment and ManagementPharmacology and Obesity TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins

The DOI matches its Crossref record; 239 of the 242 references it cites were found in a registry or an index.

GLP-1 receptor agonists, are we witnessing the emergence of a paradigm shift for neuro-cardio-metabolic disorders?

Open access
Arredouani, Abdelilah·2025·Pharmacology & Therapeutics
DOI 10.1016/j.pharmthera.2025.108824
Open this paper in CoChat — free account

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as groundbreaking therapeutic agents in managing a spectrum of metabolic disorders, demonstrating remarkable efficacy across multiple organ systems and disease states. These compounds are not only well-established in the treatment of type 2 diabetes (T2D) and obesity-conditions for which they have received widespread approval-but also exhibit promising potential in addressing cardiovascular disease (CVD) and Metabolic dysfunction-associated steatotic liver disease (MASLD). Recent investigations have begun to illuminate the utility of GLP-1RAs in the management of type 1 diabetes (T1D), as well as neurodegenerative disorders such as Alzheimer's and Parkinson's disease and various behavioral disorders. A plethora of clinical trials have consistently validated the capacity of GLP-1RAs to improve glycemic control, promote weight loss, and mitigate cardiovascular risk factors in individuals with T2D and obesity. While their application in T1D remains limited due to safety concerns-particularly regarding the risks of hypoglycemia and hyperglycemic ketoacidosis-emerging data suggest that GLP-1RAs may offer hepatoprotective benefits, potentially reducing liver fat content and decelerating the progression of MASLD. The neuroprotective attributes of GLP-1 RAs have garnered significant interest, with research indicating their potential to alleviate cognitive decline associated with neurodegenerative diseases. Furthermore, preliminary findings highlight the role of GLP-1 RAs in addressing behavioral disorders, emphasizing their extensive therapeutic promise. This comprehensive review synthesizes the current evidence supporting the diverse therapeutic applications of GLP-1RAs, positioning them as "magic drug" therapies for metabolic and neurological disorders. As ongoing research continues to explore innovative applications and combinations of GLP-1RAs, the landscape of disease management in metabolic and neurological contexts is poised for transformative advancements. This review will also critically assess safety considerations and underscore the need for personalized treatment strategies to optimize patient outcomes in these complex and often comorbid conditions.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.pharmthera.2025.108824

Cites

239 of 239 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 242 references

Research works printed but not linked: 8

  1. Administration, 2021, vol. 2024
  2. Azoulay, 2016, Ernst P, Canadian Network for Observational Drug Effect Studies Investigators. Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study. BMJ., 352, i581
  3. Bullock, 1996, Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor, Endocrinology, 137, 2968, 10.1210/endo.137.7.8770921 · DOI
  4. Wang, 2015, Liraglutide reduces oxidized LDL-induced oxidative stress and fatty degeneration in Raw 264.7 cells involving the AMPK/SREBP1 pathway, J Geriatr Cardiol, 12, 410
  5. Wang, 2024, Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes, JAMA Netw Open, 7, 10.1001/jamanetworkopen.2024.21305 · DOI · Paper page
  6. Yang, 2020, Exendin-4 reverses high glucose-induced endothelial progenitor cell dysfunction via SDF-1β/CXCR7-AMPK/p38-MAPK/IL-6 axis, Acta Diabetol, 57, 1315, 10.1007/s00592-020-01551-3 · DOI
  7. Yang, 2021, Effect of GLP-1/GLP-1R on the Polarization of Macrophages in the Occurrence and Development of Atherosclerosis, Mediators Inflamm., 2021 Mar 27, 5568159
  8. Zeng, 2023, Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis, Front Endocrinol (Lausanne), 14, 1214334, 10.3389/fendo.2023.1214334 · DOI · Paper page

Cited by

Sorted by citations

See all 38

Related

Metadata

Authors
Arredouani, A.
Affiliations
Hamad bin Khalifa University (QA)
Corresponding author
Arredouani, Abdelilah
ORCID
Arredouani, Abdelilah
Venue
Pharmacology & Therapeutics
Publisher
Elsevier BV
Published
2025-05
Volume
269
Pages
108824
ISSN
0163-7258 (ISSN-L)
DOI
10.1016/j.pharmthera.2025.108824
OpenAlex
W4407723359
Cited by
36
References
242
Citations by year
2026: 23 · 2025: 13
FWCI
4.93
Type
journal article
Language
en
Open access
Licence
Locations
  • Pharmacology & Therapeutics (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Figshare (submittedVersion, cc-by)
Funders
Hamad Bin Khalifa University Qatar Biomedical Research Institute
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
GLP-1 receptor agonists, type 2 diabetes, obesity, type 1 diabetes, non-alcoholic fatty liver disease, cardiovascular disease, neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, cognitive decline, hepatoprotection, weight loss, glycemic control, hypoglycemia, behavioral disorders, personalized treatment
MeSH terms
Glucagon-Like Peptide-1 Receptor Agonists, Animals, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Metabolic Diseases, Obesity, Neurodegenerative Diseases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review